Based in Scandinavia, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets are in late-stage clinical trials for the symptomatic treatment of PD: mesdopetam (D3 antagonist) and pirepemat (PFC enhancer).
IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD), a complex and progressive neurodegenerative condition with huge unmet need. IRLAB’s proprietary in-house developed ISP research platform is at the heart of its drug discovery engine and has been validated by the progress of its two lead assets mesdopetam and pirepemat, both of which have novel mechanisms of action. Mesdopetam, an oral D3 antagonist, is currently in a global Phase IIb/III study for levodopa-induced dyskinesias (PD-LIDs). Top-line data expected in H122 will define the pivotal trials required for approval. Pirepemat is an oral prefrontal cortex (PFC) enhancer currently in development for the treatment of impaired balance and falls in PD (PD-Falls). A global Phase IIb study is expected to start in H121. IRLAB is funded to key inflection points in 2022 of proof-of-concept data for both assets. After this we expect partnering deals to facilitate Phase III development and potential commercialisation strategies.
PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.